LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
Main Article Content
Keywords
chronic active Epstein-Barr virus, lymphocyte subsets, programmed cell death protein 1, programmed death-ligand 1, helper T cells 1, helper T cells 2
Abstract
Background And Objectives: Chronic active Epstein-Barr virus infection (CAEBV) is a lymphoproliferative disorder characterized by the increased numbers of EBV-infected T/natural killer (NK) cells and ongoing symptoms resembling infectious mononucleosis. Nonetheless, the exact correlation between peripheral lymphocyte subsets and the development of CAEBV remains uncertain. Methods: Consequently, we examined the levels of programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) expression, the status of EBV infection, and the frequencies of peripheral lymphocyte subpopulations in 24 patients with CAEBV and 15 EBV-seronegative donors using flow cytometry.
Results: Patients with CAEBV showed a notable rise in the expression levels of PD-1 and PD-L1 in peripheral T and NK cells compared to healthy donors (P < 0.05). The induction of PD-L1 expression was attributed to EBV infection. Moreover, most of the T cells infected with EBV displayed a memory phenotype characterized by the presence of CD45RO+. Additionally, patients with CAEBV showed markedly decreased frequency of helper T cells 1 (Th1) and naïve T (Tn) cells, and significantly elevated frequency of Th2 and effector-memory T (Tem) cells.
Conclusions: To summarize, EBV might evade the immune system by inducing PD-1/PD-L1 expression in peripheral T and NK cells, and promoting Th2 immune response dominance. Additionally, it may establish long-term persistence by infecting memory T cells in CAEBV.
Downloads
Abstract 1372
PDF Downloads 105
HTML Downloads 5
References
https://www.nature.com/articles/s41564-018-0334-0
PMid: 30664667
2. Chakravorty S, Afzali B, Kazemian M. EBV-associated diseases: Current therapeutics and emerging technologies. Front Immunol. 2022; 13:1059133.
https://www.frontiersin.org/articles/10.3389/fimmu.2022.1059133/full
PMid:36389670
3. Cui X, Snapper CM. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Front Immunol. 2021; 12:734471.
https://www.frontiersin.org/articles/10.3389/fimmu.2021.734471/full
PMid: 34691042
4. Leticia QM, Steven HS, Thomas T, et al. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2023; 482(1): 227-244.
https://link.springer.com/article/10.1007/s00428-022-03414-4
PMid: 36216980
5. Elias C, Elaine SJ, James RC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229-1253.
https://ashpublications.org/blood/article/140/11/1229/485458/The-International-Consensus-Classification-of
PMid: 35653592
6. Yonese I, Sakashita C, Imadome KI, et al. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020; 4(13): 2918-2926.
https://ashpublications.org/bloodadvances/article/4/13/2918/461171/Nationwide-survey-of-systemic-chronic-active-EBV
PMid: 32598475
7. Austen JJW, Charlotte JH, Claire B. Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host. Br J Haematol. 2016;175(4): 559-576.
https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14339?sid=nlm%3Apubmed
PMid: 27748521
8. Jiancheng L, Xiaokang C, Haiming W, et al. Peripheral blood lymphocyte counts in patients with infectious mononucleosis or chronic active Epstein-Barr virus infection and prognostic risk factors of chronic active Epstein-Barr virus infection. Am J Transl Res. 2021; 13 (11): 12797-12806.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661241/
PMid: 34956494
9. Ming Y, Dechao J, Hanxiao X, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17(1):129-143.
https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-018-0864-3
PMid: 30139382
10. Xi-Wen B, Hua W, Wen-Wen Z, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol. 2016; 9(1):109-121.
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-016-0341-7
PMid: 27737703
11. Jie W, Junshang G, Yian W, et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nat Commun. 2022;13(1):866-885.
https://www.nature.com/articles/s41467-022-28479-2
PMid: 35165282
12. Junshang G, Jie W, Fang X, et al. Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1. Cancer Res. 2021; 81(19):5074-5088.
https://aacrjournals.org/cancerres/article/81/19/5074/670309/Epstein-Barr-Virus-Encoded-Circular-RNA-CircBART2
PMid: 34321242
13. Yue S, Jingshi W, Yini W, et al. PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection. Clin Microbiol Infect. 2023; 29(6): e7-e13
https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(23)00039-3/fulltext
PMid: 36702399
14. Sebastian FP, Oscar S, Yasodha N. Defining the elusive boundaries of chronic active Epstein-Barr virus infection. Haematologica. 2018; 103(6): 924-927.
https://haematologica.org/article/view/8487
PMid: 29866887
15. Benjamin F, David B, Julie B, et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. J Exp Med. 2020; 217(11): e20192262.
https://rupress.org/jem/article/217/11/e20192262/152032/Rapid-identification-and-characterization-of
PMid: 32812031
16. Ann WNA, Carey LS, Alyssa L, et al. Naïve CD4+ T Cell Lymphopenia and Apoptosis in Chronic Hepatitis C Virus Infection Is Driven by the CD31+ Subset and Is Partially Normalized in Direct-Acting Antiviral Treated Persons. Front Immunol. 2021; 12: 641230.
https://www.frontiersin.org/articles/10.3389/fimmu.2021.641230/full
PMid: 33912168
17. Ann WNA, Carey LS, Lenche K, et al. Variable Normalization of Naïve CD4+ Lymphopenia and Markers of Monocyte and T Cell Activation over the Course of Direct-Acting Anti-Viral Treatment of Chronic Hepatitis C Virus Infection. Viruses. 2021; 14(1): 50-60.
https://www.mdpi.com/1999-4915/14/1/50
PMid: 35062255
18. Poonam S, Bhagyashri T, Prachi A, et al. Lymphopenia with Altered T Cell Subsets in Hospitalized COVID-19 Patients in Pune, India. Viral Immunol. 2023; 36(3): 163-175.
https://www.liebertpub.com/doi/10.1089/vim.2022.0123?url_ver=Z39.882-003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
PMid: 36897333
19. Quirin N, Marc S, Florian W, et al. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. Front Immunol. 2020; 11: 581338.
https://www.frontiersin.org/articles/10.3389/fimmu.2020.581338/full
PMid: 33123167
20. Zhanfeng L, Xue D, Zhaoqi Z, et al. Age‐related thymic involution: Mechanisms and functional impact. Aging Cell. 2022; 21(8): e13671.
https://onlinelibrary.wiley.com/doi/10.1111/acel.13671
PMid: 35822239
21. Hui S, Chen Y, Ya-Nan G, et al. Recirculating Th2 cells induce severe thymic dysfunction via IL-4/STAT6 signaling pathway. Biochem Biophys Res Commun. 2018; 501(1): 320-327.
https://www.sciencedirect.com/science/article/pii/S0006291X18310799
PMid: 29738764
22. Francesco A, Chiara R, Sergio R. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3): 626-35.
https://www.jacionline.org/article/S0091-6749(14)01585-1/fulltext
PMid: 25528359
23. Weihang L, Jindong H, Weifang X, et al. Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma. Front Immunol. 2022; 13: 974066.
https://www.frontiersin.org/articles/10.3389/fimmu.2022.974066/full
PMid: 36032162
24. Charles AD. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10): 612-632.
https://www.nature.com/articles/s41584-019-0277-8
PMid: 31515542
25. Punniyakoti VT, Srinivasan R, Poojitha M, et al. Modulation of IL-33/ST2 signaling as a potential new therapeutic target for cardiovascular diseases. Cytokine Growth Factor Rev. 2023; 71-72: 94-104.
https://www.sciencedirect.com/science/article/pii/S1359610123000266?via%3Dihub
PMid: 37422366
26. Jochen S, Alexander O, Elizabeth O, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23(5): 479-90.
https://www.cell.com/immunity/fulltext/S1074-7613(05)00311-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761305003110%3Fshowall%3Dtrue
PMid: 16286016
27. Jaewoo H, Soohyun K, P CL. Interleukin-33 and ST2 Signaling in Tumor Microenvironment. J Interferon Cytokine Res. 2019; 39(1): 61-71.
https://www.liebertpub.com/doi/10.1089/jir.2018.0044?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
PMid: 30256696
28. Corinne C, Jean-PG. Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine. Cytokine. 2022; 156: 155891-155906.
https://www.sciencedirect.com/science/article/pii/S1043466622001004?via%3Dihub
PMid: 35640416
29. Wenyi J, Jingyao L, Ying Y, et al. IL‐33/ST2 as a potential target for tumor immunotherapy. Eur J Immunol. 2021; 51(8): 1943-1955.
https://onlinelibrary.wiley.com/doi/10.1002/eji.202149175
PMid: 34131922
30. Siyan C, Luxi W, Lirong P, et al. Hepatitis B virus X protein (HBx) promotes ST2 expression by GATA2 in liver cells. Mol Immunol. 2020; 123: 32-39.
https://www.sciencedirect.com/science/article/pii/S016158901930848X?via%3Dihub
PMid: 32413787
31. Tiago LF, Andreas HG, Christian L, et al. Macrophage: A Potential Target on Cartilage Regeneration. Front Immunol. 2020; 11(11):111-120.
https://www.frontiersin.org/articles/10.3389/fimmu.2020.00111/full
PMid: 32117263
32. Anna B, Slaven C, Valentina B, et al. IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis. Eur Respir J. 2019; 54(3): 1900154-1900165.
https://erj.ersjournals.com/content/54/3/1900154.long
PMid: 31320452
33. Carl RH, Bojana SM, Crissy F, et al. The role of Interleukin 1 receptor antagonist in mesenchymal stem cell‐based tissue repair and regeneration. Biofactors. 2020; 46(2): 263-275.
https://iubmb.onlinelibrary.wiley.com/doi/10.1002/biof.1587
PMid: 31755595
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.